1756-8722

Journal of Hematology & Oncology

Springer (Biomed Central Ltd.)

View prefix report (10.1186)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 1637 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact1637 DOIs
2

Add abstracts to 1179 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact1179 DOIs
3

Add license metadata to 589 records

License metadata tells indexers and readers how each article may be reused.

Medium impact589 DOIs

DOIs for this ISSN

Showing the top 5 of 2183 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Tumor-associated macrophages: from basic research to clinica… (10.1186/s13045-017-0430-2)
Abstract ORCID License
215.54 747
2 Exosomes derived from miR-122-modified adipose tissue-derive… (10.1186/s13045-015-0220-7)
Abstract ORCID License
210.26 635
3 Wnt/beta-catenin pathway: modulating anticancer immune respo… (10.1186/s13045-017-0471-6)
Abstract ORCID License
208.79 607
4 Tumor-recruited M2 macrophages promote gastric and breast ca… (10.1186/s13045-017-0408-0)
Abstract ORCID License
195.07 398
5 Safety, pharmacokinetics, and antitumor properties of anloti… (10.1186/s13045-016-0332-8)
Abstract ORCID License
191.90 361
6 New development in CAR-T cell therapy (10.1186/s13045-017-0423-1)
Abstract ORCID License
189.09 331
7 Grading of cytokine release syndrome associated with the CAR… (10.1186/s13045-018-0571-y)
Abstract ORCID License
188.89 329
8 Paxillin: a crossroad in pathological cell migration (10.1186/s13045-017-0418-y)
Abstract ORCID License
188.29 323
9 Long-term survival in patients treated with ruxolitinib for… (10.1186/s13045-017-0527-7)
Abstract ORCID License
182.35 269
10 PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathwa… (10.1186/s13045-016-0341-7)
Abstract ORCID License
182.23 268
11 T cells in multiple myeloma display features of exhaustion a… (10.1186/s13045-016-0345-3)
Abstract ORCID License
181.50 262
12 Current status and perspectives in translational biomarker r… (10.1186/s13045-016-0277-y)
Abstract ORCID License
181.25 260
13 Current status and perspectives of patient-derived xenograft… (10.1186/s13045-017-0470-7)
Abstract ORCID License
181.12 259
14 Chimeric antigen receptor T cells: a novel therapy for solid… (10.1186/s13045-017-0444-9)
Abstract ORCID License
180.49 254
15 Bispecific antibodies and their applications (10.1186/s13045-015-0227-0)
Abstract ORCID License
179.58 247
16 ABT-199 (venetoclax) and BCL-2 inhibitors in clinical develo… (10.1186/s13045-015-0224-3)
Abstract ORCID License
179.19 244
17 The consensus on indications, conditioning regimen, and dono… (10.1186/s13045-018-0564-x)
Abstract ORCID License
179.19 244
18 Third-generation inhibitors targeting EGFR T790M mutation in… (10.1186/s13045-016-0268-z)
Abstract ORCID License
177.27 230
19 Chimeric antigen receptor T cell (CAR-T) immunotherapy for s… (10.1186/s13045-018-0568-6)
Abstract ORCID License
176.70 226
20 Circular RNAs in cancer: an emerging key player (10.1186/s13045-016-0370-2)
Abstract ORCID License
176.41 224
21 Acalabrutinib (ACP-196): a selective second-generation BTK i… (10.1186/s13045-016-0250-9)
Abstract ORCID License
176.27 223
22 Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer th… (10.1186/1756-8722-6-88)
Abstract ORCID License
175.68 219
23 The roles of mesenchymal stem cells in tumor inflammatory mi… (10.1186/1756-8722-7-14)
Abstract ORCID License
175.68 219
24 Chidamide in relapsed or refractory peripheral T cell lympho… (10.1186/s13045-017-0439-6)
Abstract ORCID License
175.53 218
25 Cocktail treatment with EGFR-specific and CD133-specific chi… (10.1186/s13045-016-0378-7)
Abstract ORCID License
174.32 210
26 Therapeutic strategies of drug repositioning targeting autop… (10.1186/s13045-017-0436-9)
Abstract ORCID License
173.70 206
27 LncRNAs H19 and HULC, activated by oxidative stress, promote… (10.1186/s13045-016-0348-0)
Abstract ORCID License
172.41 198
28 Anti-claudin 18.2 antibody as new targeted therapy for advan… (10.1186/s13045-017-0473-4)
Abstract ORCID License
170.39 186
29 Second-generation inhibitors of Bruton tyrosine kinase (10.1186/s13045-016-0313-y)
Abstract ORCID License
169.51 181
30 CAR-T cells targeting CLL-1 as an approach to treat acute my… (10.1186/s13045-017-0553-5)
Abstract ORCID License
169.33 180
31 TTBK2 circular RNA promotes glioma malignancy by regulating… (10.1186/s13045-017-0422-2)
Abstract ORCID License
169.15 179
32 STAT inhibitors for cancer therapy (10.1186/1756-8722-6-90)
Abstract ORCID License
167.66 171
33 Upfront haploidentical transplant for acquired severe aplast… (10.1186/s13045-017-0398-y)
Abstract ORCID License
167.66 171
34 Epithelial-to-mesenchymal plasticity of cancer stem cells: t… (10.1186/s13045-016-0307-9)
Abstract ORCID License
167.47 170
35 Activity of pembrolizumab in relapsed/refractory NK/T-cell l… (10.1186/s13045-018-0559-7)
Abstract ORCID License
167.47 170
36 Genetic alterations of m6A regulators predict poorer surviva… (10.1186/s13045-017-0410-6)
Abstract ORCID License
166.70 166
37 Exosomal proteins as potential markers of tumor diagnosis (10.1186/s13045-017-0542-8)
Abstract ORCID License
166.51 165
38 EGFR C797S mutation mediates resistance to third-generation… (10.1186/s13045-016-0290-1)
Abstract ORCID License
165.91 162
39 Circular RNAs: a new frontier for cancer diagnosis and thera… (10.1186/s13045-018-0569-5)
Abstract ORCID License
165.91 162
40 Bleeding, thrombosis, and anticoagulation in myeloproliferat… (10.1186/s13045-016-0242-9)
Abstract ORCID License
165.71 161
41 Predominant cerebral cytokine release syndrome in CD19-direc… (10.1186/s13045-016-0299-5)
Abstract ORCID License
165.31 159
42 Retreatment with brentuximab vedotin in patients with CD30-p… (10.1186/1756-8722-7-24)
Abstract ORCID License
164.90 157
43 Daratumumab: a first-in-class CD38 monoclonal antibody for t… (10.1186/s13045-016-0283-0)
Abstract ORCID License
164.69 156
44 Increase of PD-L1 expressing B-precursor ALL cells in a pati… (10.1186/s13045-015-0213-6)
Abstract ORCID License
164.27 154
45 miR-182-5p promotes hepatocellular carcinoma progression by… (10.1186/s13045-018-0555-y)
Abstract ORCID License
164.06 153
46 A new insight in chimeric antigen receptor-engineered T cell… (10.1186/s13045-016-0379-6)
Abstract ORCID License
163.42 150
47 Natural compounds targeting major cell signaling pathways: a… (10.1186/s13045-016-0373-z)
Abstract ORCID License
162.99 148
48 Cancer-associated fibroblasts promote the progression of end… (10.1186/s13045-015-0231-4)
Abstract ORCID License
162.77 147
49 Homoharringtonine and omacetaxine for myeloid hematological… (10.1186/1756-8722-7-2)
Abstract ORCID License
162.55 146
50 Haploidentical allograft is superior to matched sibling dono… (10.1186/s13045-017-0502-3)
Abstract ORCID License
162.55 146